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1. Background
  Dengue fever (DF) is a mosquito born viral infection 
typically characterized by symptoms like abrupt onset of 
high grade fever[(39-40)曟], retro-bulbar pain, muscular 
pain, joint pain, malaise, nausea, rashes, lymphadenopathy 
and thrombocytopenia. Complicated form of dengue is 
dengue hemorrhagic fever (DHF). It may lead to bleeding 
from nose, gums and nearly fatal internal hemorrhage 
causing hypovolemic shock known as dengue shock 
syndrome (DSS)[1,2]. 
  Unlike believed by many, dengue is not a new disease, 
first written evidence of dengue like disease comes from an 
old Chinese medical encyclopedia of 992. However, in 18th 
and 19th century mosquito vector, Aedes aegypti and dengue 
virus started spreading to new geographical location due to 
increased volume of trade and shipping between different 
continents[1]. In the recent decades incidence of dengue 
has increased dramatically. Now almost two-fifth of world’s 
population (2.5 million) is at risk of dengue and there is 
no specific treatment for dengue[3]. This has raised alarm 
among the public health professionals, across the globe, to 
find out the ways to prevent it.
  Objective of this review is to discuss various aspects 
related to dengue, its epidemiology, available preventive 
methods, need for vaccine and challenges in its 
development. 
Dengue fever is a mosquito born viral infection, and the complicated form of dengue is dengue 
hemorrhagic fever (DHF). In the recent decades incidence and distribution of dengue has 
increased dramatically. Dengue viruses belong to family flaviviridae with four serotypes and 
are transmitted mainly by mosquito Aedes aegypti. Today almost two-fifth of world’s population 
(2.5 million) is at risk of dengue and no specific antiviral drug or vaccine is available against 
it. Uncontrolled population growth in Africa and South East Asia has increased number of 
susceptible hosts in urban and semi urban areas. About 40% of world population resides in the 
high risk area for dengue transmission. According to latest estimates by WHO, yearly 50 to 100 
million infections occur globally, this includes around 500 000 DHF and 22 000 deaths, mostly 
among children. Only symptomatic treatment in the form of analgesic, antipyretics and body fluid 
management is provided to the patient. Prevention strategies mainly focus on two approaches, 
firstly on activities to control vector and secondly on activities to protect human from mosquito 
bite but there is always concerns regarding their sustainably and effectiveness. Theoretically 
development of an effective dengue vaccine is feasible and production of an effective and 
affordable vaccine could be a viable option to save humans from this dreadful disease. 
Conceptually vaccine production is possible, but it has to be tetravalent, providing immunity 
against all serotypes. Few candidate vaccines are in advance stage of their development; however 
international cooperation is needed to make these vaccines available on cheaper rates to the 
poor and vulnerable countries. Objective of this review is to discuss various aspects related to 
dengue, its epidemiology, available preventive methods, need for vaccine and challenges in its 
development. 
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2. Epidemiology
  Dengue viruses belong to family flaviviridae with four 
serotypes (dengue-1, dengue-2, dengue-3, and dengue-4) 
and are transmitted mainly by mosquito Aedes aegypti[4]. 
Principal hosts for dengue virus are human and mosquito, 
mosquito remains infected though out the life but only 
human develop illness once they are infected. Infection 
with one serotype provides lifelong immunity against that 
serotype, in some instances short life cross immunity is also 
found for few months[1,5,6]. 
  The virus sustain in the Asia and Africa probably through 
vertical transmission in mosquitoes and with regular 
amplification in non human primates. Mosquito Aedes 
aegypti has adopted itself to survive in close vicinity to 
human settlement. Aedes aegypti is found predominantly 
between 350 N and 350 S throughout the globe. For many 
reasons it is an efficient vector, it can breed and multiply 
in close proximity to humans; it feeds on human blood; it 
is active just after sunrise or just before sunset and it bites 
several people to have a single blood meal[7].  
  In the last few decades incidence and distribution of 
dengue has increased significantly. Uncontrolled population 
growth in Africa and South East Asia has increased number 
of susceptible hosts in urban and semi urban areas. Rapid 
and unmanaged urbanization in tropics has also provided 
with suitable breeding environment for Aedes aegypti. 
Inadequate management of solid wastes like, disposable 
containers, used tires and other object which can collect 
rain or waste water provides suitable place for larvae growth.
  In addition to it ever increasing air travel between 
endemic and non-endemic regions has increased the risk 
of introducing virus to non endemic areas and subsequently 
change them to hypo endemic (one serotype) or hyper 
endemic regions (multiple serotype present)[8]. Dengue 
typically spreads in tropical region during rainy, humid and 
warm season. However due to global warming it is expected 
that infection will further extend both in longitude and 
altitude. Episodes of dengue can also be expected during 
low rain fall season due to favorable increase in temperature 
and available artificial man made breeding sites[9]. 
  Today about 40% of world population resides in the high 
risk area for dengue transmission. According to latest 
estimates by WHO, yearly 50 to 100 million infections occur 
globally, including around 500 000 DHF and 22 000 deaths, 
mostly among children. There is sharp increase in number 
of countries reporting cases, prior to 1970 only 9 countries 
reported dengue case, since then number has increased 
many fold and continues to rise[10]. Dengue is predominantly 
endemic in tropical countries, which includes 100 countries 
across Asia, Africa, America, Pacific and Caribbean 
islands[11].
3. Current preventive measures against dengue
  No specific antiviral drug or vaccine is available against 
dengue[12]. Only symptomatic treatment in the form of 
analgesic, antipyretics and body fluid management is 
provided to the patient[13]. However Nonsteroidal anti-
inflammatory drugs (NSAIDS) should be avoided due to 
associated risk of increased bleeding[14]. In the absence of 
treatment most of the public health efforts are put together 
in prevention of this dreadful disease. Prevention strategies 
mainly focus on two approaches, firstly on activities to 
control vector and secondly on activities to protect human 
from mosquito bite. 
3.1. Activities for vector control
  Prime aim of these activities is to control proliferation 
of vector’s population. It can be achieved through 
environmental, chemical or biological control measures. 
Environmental management includes periodical cleaning/
draining of objects like flower pots, air conditioners, water 
coolers, roof top and bowl of domestic animal which can 
retain water. It also emphasize on efficient and reliable 
water supply to households, so as need for the water storage 
can be minimized. However, if storage is unavoidable jars 
or containers should be covered with lid. Environmental 
management also focus on 3 R’s- “Reduce, Reuse, Recycle” 
of solid waste management. Some studies, from El Salvador, 
has shown that solid wastes like discarded plastic containers 
and unused tires, infested with larva, were risk factor for 
dengue infection[15].
  Chemical control of vector in not new, in beginning of 
20th century Cuba and Panama used oil to destroy Aedes 
habitat, followed by DDT use from 1940’s onward. After the 
initial success, resistance to DDT started emerging by 1960’s. 
Subsequently other insecticides like organophosphates 
(malathion, fenthion, and temephos) were used, with 
different level of success, to control Aedes agypti vector[3]. 
Chemicals are not target/organism specifics; it not only 
causes environmental degradation but beside this has many 
harmful effects on human health.
  Biological methods like use of larvicidal fish or biocides to 
reduce breeding of mosquitoes in household water containers 
and small natural water bodies have been tried. However, 
their effectiveness is not well proven and evidences are 
based on few small field-trials. These organisms are 
expensive to grow; further their application to water bodies 
with fluctuating pH and temperature (sunlight) is limited[3]. 
Reluctance of the residents from using larvicidal, though 
safe, in potable water also limits their application for long 
term suppression of Aedes agypti population[15]. 
3.2. Activities to prevent mosquito bites
  It primarily include wearing trousers and long sleeves 
cloths, application of topical mosquito repellent and 
putting wired mesh on doors and windows to prevent 
mosquito’s entry into house[14]. These measures have their 
own limitations because of the reliance on individual 
responsibility and behavior.
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3.3. Limitations of current preventive activities
  Above discussed preventive activities largely depends 
upon community participation. Behavioral change 
program not only takes a long time but are also resource 
intensive. Vector control program in many countries are 
underfunded and lack human resources. Unfortunately 
during low transmission season limited resources are 
channeled to different activities and subsequently vector 
population rises once again. Sustained dengue vector control 
program requires coordination among health, municipal, 
administration and urban planners which seldom is a case 
in most of the countries. No doubt that these activities can 
reduce burden of disease but there is always concerns 
regarding their sustainably. 
4. Vaccine-prospects and challenges 
  Thought the dengue virus was discovered more than 
seventy years back but vaccine against dengue is not 
available till date. However, at the same time an effective 
vaccine against yellow fever and Japanese encephalitis 
caused by viruses of same family, flaviviridae, is 
available[16,17]. This led many scientists to believe that 
development of vaccine against dengue virus is possible. 
4.1. Is development of dengue vaccine possible?
  Theoretically development of an effective dengue vaccine 
is feasible. Dengue fever is an acute disease in which 
replication of the virus is controlled after the initial 3-7 days 
of viraemia[18]. Individuals once infected with one serotype 
of dengue virus are immune to rechallenge with the same 
serotype. In small percentage of population, short life, 
limited cross immunity is also found. Further, experimental 
studies on mice have show that passive inoculation of 
virus specific antibodies prevents them from subsequent 
challenge[19].  Therefore, development of vaccine against 
dengue virus is given high priority by scientific community 
as well as by WHO. 
4.2. Problem associated with dengue vaccine development
  Gaps in the knowledge about pathogenesis of DHF and 
absence of perfect animal model for dengue disease are two 
major limiting factors in successful development of vaccine. 
In a series of studies it was found that risk of developing 
DHF was 15-80 times more in persons those who are infected 
second time than in those who are infected first time[17]. 
There is evidence supporting that pre-existing heterotypic 
dengue antibody is a risk factor for the development of 
DHF, therefore, any effective vaccine should be tetravalent 
and provide immunity against all four serotypes of dengue 
virus. It has been difficult to produce an effective tetravalent 
formulation which retains its immunogenicity against all 
four serotypes and further it require complicated multi dose 
immunization regime[18]. 
4.3. Dengue vaccines candidates
  In the past seventy years many attempts have been made 
to produce vaccine against dengue virus. Only few could 
overcome the unusual interplay between human immune 
response and dengue virus. However, in 2001 WHO took 
initiative to fasten the progress towards vaccine development 
by bringing together different phase III trials centers under 
a single umbrella of Pediatric Dengue Vaccine Initiative 
(PDVI)[17]. Various organizations have used different 
molecular technology to develop dengue vaccines. Following 
is a brief account of some of the most important, somewhat 
successful, vaccine candidates in different phases of clinical 
trials.
  Historically, production of live attenuated viruses by serial 
passage through nonhuman cell is supposed to be most 
preferred method to produce viral vaccine. Two vaccines 
both using attenuated viruses, first by Mahidol University, 
Thailand and second by Walter Reed Army Institute of 
Research, USA are in advance stage of development. The 
Thai tetravalent vaccine, licensed by Aventis Pasture, has 
show 80%-90% seroconversion in the children, against all 
four serotypes after two doses. Same seroconversion results 
were shown in the adult volunteers by, GlaskoSmithKline 
licensed USA tetravalent vaccine. However concerns have 
been raised about possible imbalance between immune 
response generated to different antigens, which may lead 
to either incomplete protection or enhance severity of 
disease[17]. Further attenuated vaccine virus may also attain 
virulence through mutation.
  Evolution of chimeric dengue vaccine is a very important 
step to overcome these potential hurdles. This approach uses 
DNA recombinant technology to produce live attenuated viral 
vaccine. Chimeric virus is created by replacing structural 
protein genes of the target virus with corresponding genes of 
another virus. Robbert et al have created a most advanced 
chimeric yellow fever/dengue virus, ChimericVax-DEN[20]. 
Clinical trials are in progress to establish their potency 
in production of an effective vaccine. Attempts have also 
been made by some groups to elicit immune response by 
delivering nonstructural proteins of dengue virus through 
recombinant virus vector. This technique was successful 
to generate protective immunity in the animal models. 
However, due to lack of complete knowledge about these 
proteins, concern regarding their safely still remains[17]. 
Recently efforts are also made to utilize recombinant DNA 
technology such as synthetic consensus (SynCon) human 
codon optimized DNA vaccine, to manufacture an effective 
vaccine against all four serotypes of dengue virus[21, 22]. 
Thus conceptually development of an effective dengue 
vaccine is feasible and few promising candidate vaccines 
are in pipeline. Still it remains a challenge to scientific 
community. 
4.4. Will vaccine be a cost effective solution?
  Many concerns have been raised regarding cost 
effectiveness of the use of vaccine in comparison to medical 
Kuldeep Kumar et al./Asian Pacific Journal of Tropical Medicine (2010)997-10001000
treatment of dengue. Shepard et al in  their 1993 study, 
using treatment cost $ 200 and vaccine cost $ 17.5, found 
that medical treatment is more cost effective in the countries 
like, Thailand, where heath system is well developed. 
However, same group concluded that vaccine will be more 
cost effective in their 2004 study. This difference was 
explained on the basis of including other indirect costs 
in later analysis. In 2004 study they included cost of non 
hospitalized cases, indirect costs, vaccine cost $0.50 and 
treatment cost as $139[23]. Cost effectiveness is context 
specific, therefore an individual country should carefully 
consider all important components like incidence of disease, 
cost of treatment, direct medical cost, indirect cost (loss 
of daily wages), vaccine cost, immunization cost, cost of 
treatment of vaccine side effects and other intangible costs, 
before arriving to any decision regarding cost effectiveness 
of a vaccine.
 
5. Conclusions 
  Worldwide, dengue cases are on rise. Tropical countries 
are particularly under treat, but increase in air travel 
between endemic and non-endemic areas has put many 
more countries under its bane. It is expected that this 
problem will further escalate as a result of global warming 
and rapid unmanaged urbanization. Preventive measures 
through vector control largely depend upon community 
participation. This needs a sustained motivation and 
periodic resource intensive interventions, which might not be 
economically sustainable in long run. Moreover, due to poor 
surveillance system in many countries burden of disease 
is mostly underestimated. It is expected that magnitude of 
the problem might be more than what is estimated on the 
presently available data. Production of an effective and 
affordable vaccine could be a viable option to save humans 
from this dreadful disease. Conceptually vaccine production 
is possible, but it has to be tetravalent, providing immunity 
against all serotypes. Few candidate vaccines are in 
advance stage of their development; however, international 
cooperation is needed to make these vaccines available on 
cheaper rates to the poor and vulnerable countries.
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